Ajaduo 10mg/5mg Tablet

PRODUCT INTRODUCTION

Ajaduo 10mg/5mg Tablet is a pharmaceutical formulation designed to address the complex needs of patients with type 2 diabetes mellitus. This tablet combines two potent active ingredients, a dipeptidyl peptidase-4 (DPP-4) inhibitor called Teneligliptin and a sodium-glucose co-transporter 2 (SGLT2) inhibitor named Empagliflozin. The synergistic action of these components makes Ajaduo 10mg/5mg Tablet a remarkable addition to the arsenal of medications available for managing diabetes.

USES OF Ajaduo 10mg/5mg Tablet

Ajaduo 10mg/5mg Tablet is primarily prescribed for the management of type 2 diabetes mellitus, a metabolic disorder characterized by insulin resistance and impaired insulin secretion. It is indicated for use in adult patients who are unable to achieve glycemic control with diet and exercise alone. This medication works by lowering blood glucose levels through multiple mechanisms.

BENEFITS OF Ajaduo 10mg/5mg Tablet

• Dual Mechanism of Action: Ajaduo 10mg/5mg Tablet exerts its therapeutic effects through two distinct mechanisms. Teneligliptin enhances insulin secretion by inhibiting DPP-4 enzyme activity, thereby increasing the concentration of active incretin hormones like GLP-1. Empagliflozin, on the other hand, promotes the excretion of glucose through the urine by inhibiting SGLT2 receptors in the kidneys. This dual action helps in lowering blood glucose levels more effectively than either component alone.
• Improved Glycemic Control: Clinical studies have demonstrated that Ajaduo 10mg/5mg Tablet is effective in reducing HbA1c levels, a key marker of long-term glucose control. By optimizing glycemic control, this medication helps to mitigate the risk of diabetes-related complications such as cardiovascular disease, neuropathy, and nephropathy.
• Weight Loss: Empagliflozin, the SGLT2 inhibitor component of Ajaduo 10mg/5mg Tablet, has been associated with modest weight loss in patients with type 2 diabetes. This effect is attributed to the calorie loss resulting from the excretion of glucose in the urine. For individuals struggling with obesity or overweight, this additional benefit can contribute to overall health improvement.
• Cardiovascular Protection: Recent clinical trials have revealed that Empagliflozin, one of the active ingredients in Ajaduo 10mg/5mg Tablet, offers significant cardiovascular benefits beyond glycemic control. It has been shown to reduce the risk of major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death, in patients with established cardiovascular disease or high cardiovascular risk.

SIDE EFFECTS OF Ajaduo 10mg/5mg Tablet

While Ajaduo 10mg/5mg Tablet offers numerous benefits in the management of type 2 diabetes mellitus, it is essential to be aware of potential side effects associated with its use. Common side effects may include:

• Hypoglycemia: As with many antidiabetic medications, Ajaduo 10mg/5mg Tablet may lower blood glucose levels excessively, leading to hypoglycemia. Patients should be educated about the signs and symptoms of hypoglycemia and instructed on appropriate measures to manage this condition, such as consuming glucose-containing foods or beverages.
• Genital Mycotic Infections: SGLT2 inhibitors like Empagliflozin have been associated with an increased risk of genital mycotic infections, such as yeast infections in women and balanitis in men. Patients should be advised to maintain good hygiene and promptly report any symptoms of genital itching, redness, or discharge to their healthcare provider.
• Urinary Tract Infections: Another potential side effect of SGLT2 inhibitors is an increased risk of urinary tract infections. Patients should be encouraged to stay adequately hydrated and practice good urinary hygiene to reduce the likelihood of infection. Symptoms such as dysuria, frequency, urgency, or hematuria should be promptly evaluated by a healthcare professional.
• Volume Depletion and Dehydration: Empagliflozin can cause diuresis and natriuresis, leading to volume depletion and dehydration, particularly in elderly patients or those taking concomitant diuretic medications. Patients should be monitored for signs of dehydration, such as dizziness, orthostatic hypotension, or decreased urine output, and advised to maintain adequate fluid intake.